AstraZeneca offloads headache drug Zomig to Grünenthal to raise $300M cash
admin 7th June 2017 Uncategorised 0AstraZeneca this week had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all, the U.K. company continues to struggle and so will sell yet another asset to raise cash while CEO Pascal Soriot works to right the ship.
More: AstraZeneca offloads headache drug Zomig to Grünenthal to raise 0M cash
Source: fierce